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Introduction
Insulin-like growth factor-1 (IGF-1) is an effector hormone
which is essential for normal growth in humans and has an
important role in mediating the effects of growth hormone 
(GH) (1,2,3). In the circulatory system, IGF-1 forms a terenary
complex with IGF-binding protein-3 (IGFBP-3) and the acid-labile
subunit (4,5). This complex serves as a circulatory reservoir for
IGF-1. 
Several studies have shown that the serum levels of IGF-1
and IGFBP-3 are GH-dependent (6). Serum IGF-1 and IGFBP-3
concentrations are decreased in patients with GH deficiency 
and increased in patients with acromegaly (1,2,3,7,8,9). GH is
secreted in a pulsatile pattern. On the other hand, serum IGF-1
and IGFBP-3 have almost no pulsatile secretion and for that 
reason they are used widely in clinics (1,2,7,10,11,12,13,14,15).
Although IGF-1 and IGFBP-3 are mainly secreted by the liver,
they may be produced in several other tissues as well. Serum
IGF-1 levels increase as the child grows, reach a peak value at
puberty, and decrease with aging. Serum IGFBP-3 levels show
a relatively similar pattern (1,2,3,16,17,18,19,20,21,22,23,24,
25,26,27). Although GH is the main regulator of the production
of IGF-1 and IGFBP-3, other factors, such as gender, puberty,
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Objective: Along with growth hormone (GH) levels, measurements of serum
insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) are
used in the diagnosis of GH deficiency and in monitoring the efficacy and 
safety of long-term GH treatment. The purpose of the present study was 
to establish reference values for serum IGF-1 and IGFBP-3 in healthy Turkish
children less than 6 years of age.  
Methods: This study was designed as a multicenter project.  Five hundred
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geographical regions of Turkey, with weight and height values between the
10thand 90thpercentiles according to the national standards were included in
the study. In addition to anthropometric parameters, serum IGF-1 and IGFBP-3
levels were measured in all subjects. 
Results: Although not statistically significant, the serum IGF-1 levels in
infants at age 6 months were lower than those in infants at age 3 months.
The IGF-1 levels showed a slow increase with age. Serum IGF-1 levels
were lower in girls as compared to boys only at age 6 months. No 
correlation was found between either serum IGFBP-3 levels and body
mass index (BMI) or serum IGFBP-3 and weight and height standard 
deviation scores (SDS). A weak correlation was observed between serum
IGF-1 and IGFBP-3 concentrations. 
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e yhormones, nutrition, seasonal variations, liver and renal 
functions, gene polymorphisms also have an effect on their 
levels (1,2,3,28). Therefore, these confounding factors should
be considered when evaluating the serum IGF-1 and IGFBP-3
concentrations. It will also be helpful to have population-
specific reference ranges for serum IGF-1 and IGFBP-3 in this
evaluation. 
To our knowledge, there is a lack of large-scale studies 
analyzing the serum IGF-1 and IGFBP-3 levels young children.
The purpose of this study was to determine the normal 
reference ranges of serum IGF-1 and IGFBP-3 in healthy infants
and children younger than 6 years of age. 
Methods
This multicenter study included randomly selected healthy
infants and children (310 boys and 256 girls) younger than 6
years of age from different geographical regions of Turkey, with
weight and height measurements between the 10th and 90th
percentiles by the national standards (29,30).  Infants and 
children who had shown signs or symptoms of infection in the
preceding week were excluded. The subjects were categorized
into 8 groups according to their chronological age (Table 1). 
Measurements of height, weight, and body mass index
(BMI; kg/m2) were expressed as mean±standard deviation (SD)
values and calculated according to the national standards
(29,30,31).
Morning blood samples (2-3 mL) were obtained from all
subjects for IGF-1 and IGFBP-3 measurements. Samples were
separated by centrifugation and stored at -20°C until analysis.
All samples were studied at the same time.
Serum IGF-1 and serum IGFBP-3 levels were measured
with commercially available enzyme-linked immunosorbent
assay (ELISA) kits [Diagnostic Systems Laboratories Inc. (DSL)
DSL-10-2800 IGF-1 (Active® U.S.A)] and DSL-10-6600 
IGFBP-3 (Active® U.S.A), respectively, in accordance with the
manufacturer's recommendations.  IGF-1 and IGFBP-3 values
were expressed as ng/dL. The lower limit of detection was 0.01
ng/mL for IGF-1 and 0.04 ng/mL for IGFBP-3. The intra- and
inter-assay coefficients of variation (CV) for IGF-1 were 6.3%
and 3.3%, respectively. The intra- and inter-assay CV were
9.6% and 11.4% for IGFBP-3, in the same order.  
Approval was obtained from the Cukurova University Ethics
Committee. Families gave informed consent for their child’s
participation in the research. This study was conducted in 
accordance with the Helsinki II Declaration.
The statistical analyses were performed using SPSS 
(version 16; SPSS, Inc., Chicago, IL, USA). The data were given
as SD, mean, minimum and maximum values, and 95% 
confidence intervals (CI). The Pearson’s correlation coefficient
(r) was used to evaluate the relationship of IGF-1 and IGFBP-3
with other variables, while the Spearman’s rank correlation
coefficient was used when needed. A p-value of less than 0.05
was considered to be statistically significant. 
Results
Height SDS, weight SDS, and BMI values of all children
were within normal ranges, as shown in Table 1. Mean 
and SDS values, ranges, and 95% CIs for serum IGF-1 and
IGFBP-3 levels in both genders are shown in Table 2. Figures 1
and 2 illustrate the IGF-1 and IGFBP-3 values at different ages. 
The serum IGF-1 levels of infants in the 5.5-6.5-month age
group were found to be lower than those of infants in the 
2.5-3.5-month group (Table 2, Figure 1). 
IGF-1 level correlated with BMI in girls in the 33-39-month
age group and in boys in the age groups 21-27 and 45-51
months (r= 0.564, p= 0.012; r= 0.413, p= 0.023; and r= 0.568,
p= 0.009, respectively). By the Spearman’s method, the above
correlation was only observed in the 33-39-month age group in
girls and in the 45-51-month age group in boys. No association
was found between serum IGF-1 levels and BMI at other ages
by either method. By the Spearman’s method, a relationship
between serum IGF-1 and height SDS was detected only in
boys in the age group 57-63 months (r= 0.462, p= 0.01).
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Figure 1. Age distribution of serum IGF-1  levels (ng/mL) in both 
genders
IGF-1: insulin-like growth factor-1
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Figure 2. Age distribution of serum IGFBP-3  levels (ng/mL) in both 
genders
IGFBP-3: insulin-like growth factor binding protein-3
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200A decreased serum IGFBP-3 concentration was 
only observed in girls at 6 months of age (Table 2, Figure 2). In
contrast to IGF-1, serum IGFBP-3 levels did not increase in 
parallel to the growth of children. 
In the girls, no significant differences were detected in
serum IGF-1 levels among age groups.  On the other hand, the
girls in all age groups, except the 5.5-6.5-month group, had
higher IGF-1 values than the boys in all age groups. There was
no such relationship for IGFBP-3 levels (Table 2).
No correlations were found between either IGFBP-3 
and BMI or IGFBP-3 and height and  weight SDS. A weak 
correlation was observed between serum IGF-1 and IGFBP-3 in
some age groups.
Discussion
In this study, we established the reference intervals for
serum IGF-1 and IGFBP-3 levels in Turkish children younger
than 6 years of age. It has been reported that the serum IGF-1
levels tend to increase slowly with age in childhood, reach a
peak level at puberty, and decrease with age thereafter. Serum
IGF-1 concentrations in female children and adolescents are
slightly higher than those in their male counterparts.
Additionally, the time to reach a peak value is 2 years earlier in
females (3,16,17,18,19,20,24,25). All of these studies 
established the reference ranges for school-aged children and
adolescents and, most of the studies included relatively small
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Table 2. Serum levels (ng/dL) and 95% CI values of IGF-1 and IGFBP-3 of the subjects (mean±SD)
Girls Boys
IGF-1 IGFBP-3 IGF-1 IGFBP-3 
Age group
(months) n Mean±SD 95% CI Mean±SD 95% CI n Mean±SD 95% CI Mean±SD 95% CI
2.5-3.5 22 111.3±89.7 71.5-151.0 6255±1970 5381-7129 29 110.8±84.5 78.1-143.0 6390±2259 5330-7249
5.5-6.5 33 67.8±74.1 40.8-93.6 5514±1918 4834-6195 41 89.3±98.7 58.1-120.5 6442±1715 5901-6984
11-12 45 125.3±92.8 97.7-152.8 6721±2100 6105-7338 54 82.1±64.5 64.4-99.7 6502±2232 5892-7111
21-27 36 127.2±101.2 93.4-160.9 6049±2085 5363-6734 46 99.2±98.5 70.3-128.5 6725±1756 6403-7246
33-39 30 138.2±101.5 100.3-176.1 6750±1991 6006-7494 38 118.7±92.5 88.3-149.1 6658±1899 6033-7282
45-51 27 163.8±117.7 117.2-210.3 7201±1345 6669-7133 29 114.1±107.4 73.2-154.9 7003±2119 6197-7809
57-63 35 161.9±134.5 115.7-208.1 6494±2085 5778-7211 40 117.8±97.6 86.5-149.0 7081±1910 6470-7692
69-75 28 208.9±124.6 160.5-257.2 7392±1855 6673-8111 33 186.4±135.8 138-234.9 7312±2449 6443-8180
IGF-1: insulin-like growth factor-1, IGFBP-3: insulin-like growth factor binding protein-3, SD: standard deviation, CI: confidence interval
Table 1. Height SDS, weight SDS, and BMI of the subjects (mean±SD values)
Girls Boys
Age group n Height Weight BMI n Height Weight BMI
(months) SDS SDS SDS SDS
2.5-3.5 22 1.04±1.66 0.78±0.84 16.7±1.51 29 0.92±1.17 1.25±0.85 17.8±1.20
5.5-6.5 33 0.44±0.92 -0.08±0.79 17.1±1.27 41 0.28±1.12 0.48±0.89 18.3±1.61
11-12 45 0.89±0.54 0.32±0.69 17.0±1.43 54 0.49±1.02 0.22±0.85 17.6±1.56
21-27 36 -0.01±0.83 -0.02±0.78 16.7±1.62 46 0.19±0.86 0.05±0.73 17.0±2.07
33-39 30 -0.71±0.61 -0.44±0.79 16.1±1.28 38 -0.32±0.78 -0.01±0.86 16.5±1.50
45-51 27 -0.26±0.73 -0.07±0.75 15.6±1.35 29 -0.04±0.61 0.16±0.59 16.4±1.26
57-63 35 0.03±0.85 0.03±0.74 15.4±1.20 40 -0.12±0.83 0.19±0.70 16.2±1.57
69-75 28 -0.48±0.71 -0.18±0.54 15.9±1.20 33 -0.27±0.87 0.02±0.55 15.9±1.49
SDS: standard deviation scores, SD: standard deviation, BMI: body mass indexnumbers of young children under 6 years of age. In agreement
with previous reports, our findings also indicate that serum 
IGF-1 levels tend to increase slowly with age.  One of the
largest studies which established the reference levels for IGF-1
and IGFBP-3 was conducted on 353 children between 0 and 5
years of age and showed that serum IGF-1 levels decreased
slowly between 0 and 24 months but  increased with age 
thereafter  ( 27). . Although the decrease found during the first
24 months was not significant, the increase after 24 months
was statistically significant (27). We observed a similar non-
significant decrease in IGF-1 values in the first 6 months in the
girls and in the first 12 months in the boys and an increase
thereafter. In a limited number of subjects, Bereket et al (25)
reported that serum IGF-1 levels increased slowly at ages 4 to
6 years in healthy children. The ranges of serum IGF-1 and
IGFBP-3 concentrations at 4-6 years of age obtained in this
study were similar to our results.
Cord blood levels of IGF-1 and IGFBP-3 correlate with 
gestational age, birth weight, and birth height. However, IGF-1
and IGFBP-3 are not under the influence of GH during the
intrauterine period (32). In a prospective study, Chellakooty 
et al (33) reported that a statistically significant but weak 
association existed between serum IGF-1 and IGFBP-3 levels
and postnatal growth in infants at age 3 months who were
appropriate for gestational age (AGA) but not in those who
were small for gestational age (SGA). In the same study, 
serum IGF-1 and IGFBP-3 levels in breast-fed infants were 
significantly lower than the levels in formula-fed ones (33). In
our study, all subjects 6 months of age or less were either
exclusively breast-fed or received supplementary food in 
addition to breastfeeding. The low serum IGF-1 and IGFBP-3
concentrations in the first 6 to 12 months of age might be due
to breastfeeding during these months. It has been shown that
GH, IGF-1, and IGFBP-3 are present in mother’s milk, and the
levels increase with GH treatment (34,35). It may be that the
hormones in mother’s milk suppress the GH-IGF axis of 
the infant. Although most of the studies reported negative 
correlations between long-term breastfeeding and 
body weight, there are also studies showing a positive 
correlation (36). 
Serum IGFBP-3 levels correlate with spontaneous nocturnal
GH secretion (10). While normal concentrations of serum IGF-1
and IGFBP-3 rule out the diagnosis of GH deficiency, lower 
levels support it (11,12). Similar to serum IGF-1 levels, the 
levels of serum IGFBP-3 also increase with age, reach a peak at
puberty, though not as high as serum IGF-1, then decrease 
with increasing age (7,18). We did not detect any significant 
elevation in serum IGFBP-3 levels in infants and children
younger than 6 years. Males had slightly higher values but not
at a statistically significant level. In contrast, Chellakooty et al
(33) who measured the serum IGFBP-3 levels 3-month-old
infants (with normal birth weights), found significantly higher
values in the females. Higher concentrations of serum IGFBP-3
in female children have been noted in other studies as well
(7,21,22,25). The gender disparity in IGFBP-3 levels is more
prominent at puberty but less pronounced than that for serum
IGF-1 levels. 
Serum IGF-1 levels were shown to have a positive 
correlation with BMI. However, a precise association between
BMI and serum IGFBP-3 was not established (21,25). The 
positive correlation between serum IGF-1 and IGFBP-3 levels
and BMI is most prominent in puberty (16,25,27). In our study,
we found a weak correlation between BMI and serum IGF-1
levels in infants and young children. However, serum IGF-1 was
found to strongly correlate with BMI in other studies, 
though mostly conducted among school-aged children and 
adolescents. This finding suggests that the correlation
becomes stronger with age and pubertal development. In our
study, no association was observed between IGFBP-3 and BMI
in any age group.
Serum IGF-1 and serum IGFBP-3 levels are known to 
positively correlate with normal growth rate in older children
and adolescents and also with growth rate in children receiving
GH therapy (7,14,15). It is not always possible to show this 
relationship in cross-sectional studies, such as ours. Further
prospective studies are required to demonstrate whether this
correlation also exists in prepubertal children. 
In conclusion, this study served to establish the reference
levels for serum IGF-1 and IGFBP-3 in healthy Turkish infants
and children below 6 years of age. These values can be used as
reference values in screening for GH deficiency and also in
monitoring GH treatment for efficacy and safety in children with
GH deficiency. 
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